Holen Sie sich die Stockscreener-App
9.19
6.98%
-0.69
Handel nachbörslich:
9.19
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
OLMA Stock Soars 47% in September So Far on Second PFE Deal - MSN
OLMA,GH Options - Finviz
Olema Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
InvestingPro’s Fair Value flagged Olema stock as overvalued at $19.49 By Investing.com - Investing.com Canada
OLMA Q1 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances PipelineNegative Surprise Momentum - newsline.com
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
UBS Remains a Buy on Olema Pharmaceuticals (OLMA) - The Globe and Mail
OLMA Technical Analysis | Trend, Signals & Chart Patterns | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why Olema Pharmaceuticals (OLMA) Is Down 7.1% After Bayer OP-3136 Prostate Cancer Trial Deal And Data - Sahm
Guggenheim Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $35 - Moomoo
OLMA Stock Price, Quote & Chart | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Olema Pharmaceuticals Inc. (OLMA) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Ongoing Clinical Progress - thelegaladvocate.com
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy - Moomoo
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Tr - GuruFocus
Olema Oncology inks clinical trial collaboration with Bayer - The Pharma Letter
Olema Oncology and Bayer Partner on Clinical Trial to Evaluate OP-3136 and NUBEQA® in Metastatic Castration-Resistant Prostate Cancer 1 - Minichart
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial - GuruFocus
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
Olema oncology announces clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with Nubeqa® (darolutamide) in metastatic castration-resistant prostate cancer - marketscreener.com
Olema Oncology (NASDAQ: OLMA) inks Bayer trial deal for OP-3136 combo - Stock Titan
New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA - Stock Titan
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - Yahoo Finance
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Olema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 study - MSN
Olema Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:OLMA - Benzinga
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study - Yahoo Finance
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Olema Oncology Reports Promising Phase 1 Results for OP-3136 KAT6 Inhibitor in Advanced Solid Tumors at 2026 ASCO Meeting 12 - Minichart
Olema reports phase 1 data for cancer drug OP-3136 By Investing.com - Investing.com South Africa
Olema reports phase 1 data for cancer drug OP-3136 - Investing.com UK
Olema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid Tumors - Quiver Quantitative
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data - Stock Titan
Olema Oncology Announces Encouraging Initial Clinical Data - GlobeNewswire
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $52 - Moomoo
Olema Pharmaceuticals (OLMA) Stock Today: Drops -5.00%, Key Support at $12.26 2026-05-18Breakout Stock Alerts - newsline.com
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Olema Pharmaceuticals (OLMA) Deepens Trial Spend With Ample Cash Buffer Is Its Risk-Reward Now Clearer? - Sahm
Olema Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Bain Capital (OLMA) discloses 8.2% position including pre-funded warrant - Stock Titan
Janus Henderson (NASDAQ: OLMA) discloses 7.11M shares, 8.2% stake - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):